Uloric (febuxostat) has been shown to effectively manage hyperuricemia in patients with gout, achieving normal serum urate levels in 45-67% of patients. The treatment also reduced the risk of future gout flares and was superior to allopurinol in lowering serum urate levels.
The fixed-dose combination ACTOplus met (pioglitazone HCl and metformin HCl) was shown to be more effective in reducing hemoglobin A1c levels than either component alone, with 64% of patients reaching the goal of ≤7 percent. Additionally, the study found significant reductions in insulin resistance and fasting plasma glucose levels.
Alogliptin demonstrated significant reductions in hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes, particularly when used as monotherapy or added to existing oral anti-diabetic treatments. The study results suggest alogliptin is a effective treatment option for patients with inadequate blood sugar control.
A clinical trial using IVUS technology found that Actos reduced the atherosclerotic burden in coronary arteries compared to glimepiride, and prevented progression. The study adds to the body of cardiovascular data for Actos, showing no evidence of increased risk of heart attack or stroke.
Alogliptin, a highly selective DPP-4 inhibitor, demonstrated significant reductions in mean 4-hour plasma glucose levels across multiple doses. The study also showed sustained inhibition of plasma DPP-4 activity and improved glucose control without increased risk of hypoglycemia.